Alembic Pharmaceuticals gets revision in credit ratings
From CRISIL
Alembic Pharmaceuticals announced that CRISIL has revised the following credit ratings -1. Reaffirmed the credit rating of ''CRISIL AA+/Stable' for Rs. 850 crore limit of fund & non-fund based facilities and term loans.
2. Assigned the credit rating of ''CRISIL AA+/Stable'' for the proposed Issue of Non-Convertible Debentures of Rs. 300 crore.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content